Experimental Therapies

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


123 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
In press
 
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
Huber F., Arnaud M., Stevenson B.J., Michaux J., Benedetti F., Thevenet J., Bobisse S., Chiffelle J., Gehert T., Müller M. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14DC47CDBB48]
 
An antigen discovery pipeline integrates multi-omics data and informs immunotherapy.
Huber Florian, Bassani-Sternberg Michal Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB4C05BEE4BB]
 
PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma.
Martínez Bedoya D., Marinari E., Davanture S., Castillo Cantero L., Erraiss S., Dockerill M., Barluenga S., Winssinger N., Schaller K., Bijlenga P. et al. Cancer immunology research. Peer-reviewed.
[DOI][Pmid][serval:BIB_DA3199F2C93C]
 
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88A45E78E09C]
 
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF334A302D27]
2024
 
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.
Ghisoni E., Morotti M., Sarivalasis A., Grimm A.J., Kandalaft L., Laniti D.D., Coukos G., 2024/11. Nature reviews. Clinical oncology, 21 (11) pp. 801-817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A4CCCAE3C462]
 
Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
Martín-Lluesma S., Svane I.M., Dafni U., Vervita K., Karlis D., Dimopoulou G., Tsourti Z., Rohaan M.W., Haanen JBAG, Coukos G., 2024/10. Annals of oncology, 35 (10) pp. 860-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C3B84E4D1FD]
 
Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.
Perez MAS, Chiffelle J., Bobisse S., Mayol-Rullan F., Bugnon M., Bragina M.E., Arnaud M., Sauvage C., Barras D., Laniti D.D. et al., 2024/10. Advanced science, 11 (40) pp. e2405949. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C9B82A244FB]
Personalized cancer T-cell therapy takes the stage, mirroring vaccine success.
Chiffelle J., Harari A., 2024/08/05. The Journal of experimental medicine, 221 (8). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CEA5DB463B31]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5FCB44D6E4AA]
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells.
Croce G., Bobisse S., Moreno D.L., Schmidt J., Guillame P., Harari A., Gfeller D., 2024/04/13. Nature communications, 15 (1) p. 3211. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5F1F27C4B8D4]
A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation.
Martins F., Rosspopoff O., Carlevaro-Fita J., Forey R., Offner S., Planet E., Pulver C., Pak H., Huber F., Michaux J. et al., 2024/03/15. Cancer research, 84 (6) pp. 808-826. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_26A70ECA1060]
Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides.
Ferreira H.J., Stevenson B.J., Pak H., Yu F., Almeida Oliveira J., Huber F., Taillandier-Coindard M., Michaux J., Ricart-Altimiras E., Kraemer A.I. et al., 2024/03/15. Nature communications, 15 (1) p. 2357. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6C0EA9079104]
 
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S., Tyekucheva S., Tissot-Renaud S., Chaba K., Imbimbo M., Benedetti F., Kammler R., Hornfeld J., Munzone E., Gianni L. et al., 2024/03. European journal of cancer, 200 p. 113535. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE560AF185F]
Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol.
Kinj R., Gaide O., Jeanneret-Sozzi W., Dafni U., Viguet-Carrin S., Sagittario E., Kypriotou M., Chenal J., Duclos F., Hebeisen M. et al., 2024/03. Clinical and translational radiation oncology, 45 p. 100743. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A13C0D7F4DC1]
 
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D., Ghisoni E., Chiffelle J., Orcurto A., Dagher J., Fahr N., Benedetti F., Crespo I., Grimm A.J., Morotti M. et al., 2024/02/02. Science immunology, 9 (92) pp. eadg7995. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A58DD7E390E0]
2023
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ.
Newey A., Yu L., Barber L.J., Choudhary J.S., Bassani-Sternberg M., Gerlinger M., 2023/11/17. Cancer research communications, 3 (11) pp. 2345-2357. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_247CD6A9F993]
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M., Huber F., Arnaud M., Kraemer A.I., Altimiras E.R., Michaux J., Taillandier-Coindard M., Chiffelle J., Murgues B., Gehret T. et al., 2023/11/14. Immunity, 56 (11) pp. 2650-2663.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_809F4EAB21AB]
Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics.
Romanens L., Chaskar P., Marcone R., Ryser S., Tille J.C., Genolet R., Heimgartner-Hu K., Heimgartner K., Moore J.S., Liaudet N. et al., 2023/11/01. International journal of cancer, 153 (9) pp. 1568-1578. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA0A2EA97728]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
 
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells
Giancarlo Croce, Sara Bobisse, Dana Léa Moreno, Julien Schmidt, Philippe Guillame, Alexandre Harari, David Gfeller, 2023/09/16..
[DOI][serval:BIB_0A68625521D8]
HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection.
Obuku A.E., Lugemwa J.K., Abaasa A., Joloba M., Ding S., Pollara J., Ferrari G., Harari A., Pantaleo G., Kaleebu P., 2023/08/29. BMC immunology, 24 (1) p. 25. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62C12F4E0858]
 
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers.
Bill R., Wirapati P., Messemaker M., Roh W., Zitti B., Duval F., Kiss M., Park J.C., Saal T.M., Hoelzl J. et al., 2023/08/04. Science, 381 (6657) pp. 515-524. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17A3A9510B2F]
Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity in immunocompromised patients.
Fallet B., Foglierini M., Porret R., Alcaraz-Serna A., Sauvage C., Jenelten R., Caplanusi T., Gilliet M., Perez L., Fenwick C. et al., 2023/08. The Journal of infection, 87 (2) pp. 111-119. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9DA429039D3E]
A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics.
Li X., Pak H.S., Huber F., Michaux J., Taillandier-Coindard M., Altimiras E.R., Bassani-Sternberg M., 2023/06/26. Cell reports methods, 3 (6) p. 100479. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_124E229FADE6]
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J., Guillaume P., Schmidt J., Michaux J., Larabi A., Lau K., Perez MAS, Croce G., Genolet R., Coukos G. et al., 2023/06/13. Immunity, 56 (6) pp. 1359-1375.e13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BA5A00EAA19]
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R., Lozano L.E., Anastasio A., Lofek S., Mastelic-Gavillet B., Navarro Rodrigo B., Nguyen S., Dartiguenave F., Rodrigues-Dias S.C., Cesson V. et al., 2023/06/08. Cancers, 15 (12) p. 3114. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4F3B91EA43E2]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
 
Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development.
Kreidieh F.Y., Tawbi H.A., Alexaki A., Borghaei H., Kandalaft L.E., 2023/06. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43 pp. e391278. Peer-reviewed.
[DOI][Pmid][serval:BIB_7F5F8D78F1D1]
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L., Resche-Rigon M., Dromain C., Lamarca A., La Salvia A., de Baker L., Fehrenbach U., Pusceddu S., Colao A., Borbath I. et al., 2023/06. Journal of neuroendocrinology, 35 (6) pp. e13311. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A27AF92DDE2]
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Kraemer A.I., Chong C., Huber F., Pak H., Stevenson B.J., Müller M., Michaux J., Altimiras E.R., Rusakiewicz S., Simó-Riudalbas L. et al., 2023/05. Nature cancer, 4 (5) pp. 608-628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AFB188A208B6]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Fritah H., Graciotti M., Lai-Lai Chiang C., Huguenin-Bergenat A.L., Petremand R., Ahmed R., Guillaume P., Schmidt J., Stevenson B.J., Gfeller D. et al., 2023/04/21. iScience, 26 (4) p. 106288. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5198D931AE8]
 
Impact of Variations in the Nursing Care Supply-Demand Ratio on Postoperative Outcomes and Costs.
Agri F., Grass F., Kasmi S., Demartines N., Schäfer M., Sauvain M.O., 2023/03/01. Journal of patient safety, 19 (2) pp. 86-92. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FCAC2696FF83]
The impact of immunopeptidomics: From basic research to clinical implementation.
Shapiro I.E., Bassani-Sternberg M., 2023/03. Seminars in immunology, 66 p. 101727. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6B56B0492D5F]
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+ )T-cell epitopes.
Gfeller D., Schmidt J., Croce G., Guillaume P., Bobisse S., Genolet R., Queiroz L., Cesbron J., Racle J., Harari A., 2023/01/18. Cell systems, 14 (1) pp. 72-83.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_53359DC7F7C1]
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Lofek S., Wyss T., Melero I., de Vries IJM, Harari A., Romero P., Kandalaft L.E. et al., 2023. Frontiers in immunology, 14 p. 1119371. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_93460C0AF320]
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
Arnaud M., Coukos G., Harari A., 2023/01. Clinical and translational medicine, 13 (1) pp. e1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_803001E6E3E3]
2022
The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study.
COVIDSurg Collaborative, Adamina M., 2022/11. Colorectal disease, 24 (6) pp. 708-726. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DF2681B2CCAC]
 
Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation.
Lorusso G., Wyss C.B., Kuonen F., Vannini N., Billottet C., Duffey N., Pineau R., Lan Q., Wirapati P., Barras D. et al., 2022/09/07. Science translational medicine, 14 (661) pp. eaax8933. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F3A5420A158C]
Integrated multi-omics reveals cellular and molecular interactions governing the invasive niche of basal cell carcinoma.
Yerly L., Pich-Bavastro C., Di Domizio J., Wyss T., Tissot-Renaud S., Cangkrama M., Gilliet M., Werner S., Kuonen F., 2022/08/20. Nature communications, 13 (1) p. 4897. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A792039350C9]
 
Performance of prolonged air leak scoring systems in patients undergoing video-assisted thoracoscopic surgery segmentectomy.
Gonzalez M., Karenovics W., Bédat B., Forster C., Sauvain M.O., Triponez F., Christodoulou M., Krueger T., Perentes J.Y., 2022/08/03. European journal of cardio-thoracic surgery, 62 (3) pp. ezac100. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C88BFF9218C2]
 
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar A., Champagne J., Nagel R., Kenski J., Laos M., Michaux J., Pak H.S., Bleijerveld O.B., Mordente K., Navarro J.M. et al., 2022/08..
[DOI][WoS][Pmid][serval:BIB_9B120DBE92DE]
 
Immune pressure sculps tumor cells and trims high-quality mutations.
Bassani-Sternberg M., Harari A., 2022/07/11. Cancer cell, 40 (7) pp. 717-719. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4774C8AD358C]
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M., Rusakiewicz S., Früh M., Hayoz S., Grosso F., Pless M., Zucali P., Ceresoli G.L., Maconi A., Schneider M. et al., 2022/06. ESMO open, 7 (3) p. 100446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FA0FF9C4B3E9]
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
Arnaud M., Chiffelle J., Genolet R., Navarro Rodrigo B., Perez MAS, Huber F., Magnin M., Nguyen-Ngoc T., Guillaume P., Baumgaertner P. et al., 2022/05. Nature biotechnology, 40 (5) pp. 656-660. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18BFBDDF727B]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
 
Predictions of immunogenicity reveal potent SARS-CoV-2 CD8+ T-cell epitopes
Gfeller David, Schmidt Julien, Croce Giancarlo, Guillaume Philippe, Bobisse Sara, Genolet Raphael, Queiroz Lise, Cesbron Julien, Racle Julien, Harari Alexandre, 2022..
[DOI][serval:BIB_97E1B8EF6136]
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
Matthaiou E.I., Guo Y., Barar J., Sandaltzopoulos R., Kandalaft L.E., Li C., Coukos G., Omidi Y., 2022. BioImpacts, 12 (1) pp. 65-86. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7205BBE80A2D]
2021
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft L.E., Harari A., 2021/11/19. Cancers, 13 (22) p. 5819. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6B925EAAEE85]
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A., Sarivalasis A., de Jonge K., Thierry A.C., Huber F., Boudousquie C., Rossier L., Orcurto A., Imbimbo M., Baumgaertner P. et al., 2021/11/18. Cancers, 13 (22) p. 5801. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A292F2251A7]
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang C.L., Rovelli R., Sarivalasis A., Kandalaft L.E., 2021/09/10. Cancers, 13 (18) p. 4553. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0968A9F9CD4C]
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays.
Duchamp M., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2021/09/06. Micromachines, 12 (9) p. 1076. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_550F1A17928D]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.
Meylan S., Dafni U., Lamoth F., Tsourti Z., Lobritz M.A., Regina J., Bressin P., Senn L., Grandbastien B., Andre C. et al., 2021/07/05. BMJ open, 11 (7) pp. e049232. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_471F833F0211]
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/05/04. NPJ vaccines, 6 (1) p. 68. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2126872FC2DC]
 
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Peters S., Dafni U., Perol M., Felip E., Polito L., Pal N., Ton T.G.N., Merritt D., Morris S., Stahel R.A., 2021/05. Annals of Oncology, 32 (5) pp. 687-688.
[DOI][WoS][serval:BIB_3634E1D8C4C5]
Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma.
Schaller J., Hajjami H.M., Rusakiewicz S., Ioannidou K., Piazzon N., Miles A., Golshayan D., Gaide O., Hohl D., Speiser D.E. et al., 2021/03/30. Oncotarget, 12 (7) pp. 638-648. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BF678E4FB907]
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A. et al., 2021/03/15. NPJ vaccines, 6 (1) p. 36. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E270F9DEDE8]
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting.
Schmidt J., Smith A.R., Magnin M., Racle J., Devlin J.R., Bobisse S., Cesbron J., Bonnet V., Carmona S.J., Huber F. et al., 2021/02/16. Cell reports. Medicine, 2 (2) p. 100194. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9AA90BD897A9]
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.
Cachot A., Bilous M., Liu Y.C., Li X., Saillard M., Cenerenti M., Rockinger G.A., Wyss T., Guillaume P., Schmidt J. et al., 2021/02. Science advances, 7 (9) pp. eabe3348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FDE10B2A046]
 
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U., Martín-Lluesma S., Balint K., Tsourti Z., Vervita K., Chenal J., Coukos G., Zaman K., Sarivalasis A., Kandalaft L.E., 2021/01. European journal of cancer, 142 pp. 63-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D084831A838B]
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M., Bobisse S., Chiffelle J., Harari A., 2021. Frontiers in immunology, 12 p. 701636. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_132C3057D946]
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P., Sankar M., Herrera F.G, Benedetti F., Barras D., Thierry A.C., Dangaj D., Kandalaft L.E., Coukos G., Xenarios I. et al., 2021. Frontiers in immunology, 12 p. 633910. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E707FFE34C52]
2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O'Brien M., Pope A., Fisher P., Spicer J., Roy A., Gilligan D. et al., 2020/12. Annals of oncology, 31 (12) pp. 1734-1745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0FC8052F2621]
 
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T. et al., 2020/12. Cytotherapy, 22 (12) pp. 780-791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30851676B0A7]
Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes
Chong Chloe, Müller Markus, Pak HuiSong, Harnett Dermot, Huber Florian, Grun Delphine, Leleu Marion, Auger Aymeric, Arnaud Marion, Stevenson Brian J. et al., 2020/12. Nature Communications, 11 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_03EA897A1141]
 
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Devlin J.R., Alonso J.A., Ayres C.M., Keller GLJ, Bobisse S., Vander Kooi C.W., Coukos G., Gfeller D., Harari A., Baker B.M., 2020/11. Nature chemical biology, 16 (11) pp. 1269-1276. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_186F0AD1C570]
 
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells D.K., van Buuren M.M., Dang K.K., Hubbard-Lucey V.M., Sheehan KCF, Campbell K.M., Lamb A., Ward J.P., Sidney J., Blazquez A.B. et al., 2020/10/29. Cell, 183 (3) pp. 818-834.e13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F6095670EC38]
 
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
Iancu E.M., Kandalaft L.E., 2020/10. Current opinion in biotechnology, 65 pp. 233-241. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B35118F36861]
 
Antitumour dendritic cell vaccination in a priming and boosting approach.
Harari A., Graciotti M., Bassani-Sternberg M., Kandalaft L.E., 2020/09. Nature reviews. Drug discovery, 19 (9) pp. 635-652. Peer-reviewed.
[DOI][Pmid][serval:BIB_14F09B31BAF0]
 
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.
Ochoa de Olza M., Navarro Rodrigo B., Zimmermann S., Coukos G., 2020/09. The Lancet. Oncology, 21 (9) pp. e419-e430. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_208B57498352]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
 
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams S.F., Grimm A.J., Chiang C.L., Mookerjee A., Flies D., Jean S., McCann G.A., Michaux J., Pak H., Huber F. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e000875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B7CF92C7BCB]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/06/23. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][Pmid][serval:BIB_2DED61B64BB4]
Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.
Graciotti M., Marino F., Pak H., Baumgaertner P., Thierry A.C., Chiffelle J., Perez MAS, Zoete V., Harari A., Bassani-Sternberg M. et al., 2020/06/02. Vaccines, 8 (2). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0A84027C58CB]
 
Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma.
Dheilly E., Battistello E., Katanayeva N., Sungalee S., Michaux J., Duns G., Wehrle S., Sordet-Dessimoz J., Mina M., Racle J. et al., 2020/05/11. Cancer cell, 37 (5) pp. 674-689.e12. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C0FB07A8B571]
 
Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft L.E., Odunsi K., Coukos G., 2020/05. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40 pp. 1-13. Peer-reviewed.
[DOI][Pmid][serval:BIB_71D55C2B15BF]
Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.
Boudousquié C., Boand V., Lingre E., Dutoit L., Balint K., Danilo M., Harari A., Gannon P.O., Kandalaft L.E., 2020/01/14. Vaccines, 8 (1). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8FCD2C6F2CCA]
Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.
Germann M., Zangger N., Sauvain M.O., Sempoux C., Bowler A.D., Wirapati P., Kandalaft L.E., Delorenzi M., Tejpar S., Coukos G. et al., 2020/01/09. EMBO molecular medicine, 12 (1) pp. e10681. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F06A8D6CE8D2]
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.
Vigano S., Bobisse S., Coukos G., Perreau M., Harari A., 2020. Frontiers in immunology, 11 p. 1350. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_19C82F6CB34E]
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Bianchi V., Harari A., Coukos G., 2020. Frontiers in immunology, 11 p. 1215. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B0551F2A3933]
2019
 
Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry.
Girotra M., Thierry A.C., Harari A., Coukos G., Naveiras O., Vannini N., 2019/12/26. Journal of visualized experiments 154. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE9A27B5B4E4]
Microfluidic device performing on flow study of serial cell-cell interactions of two cell populations.
Duchamp M., Dahoun T., Vaillier C., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2019/12/09. RSC advances, 9 (70) pp. 41066-41073. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E280C4A083E]
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_313F7CD9FDBC]
Believe in yourself, and enjoy the ride.
Kandalaft L.E., 2019/11. EBioMedicine, 49 p. 22. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E37DB0DFCB10]
 
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Racle J., Michaux J., Rockinger G.A., Arnaud M., Bobisse S., Chong C., Guillaume P., Coukos G., Harari A., Jandus C. et al., 2019/11. Nature biotechnology, 37 (11) pp. 1283-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A8D08A5BC6]
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC3C085DEA43]
 
F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F575C6723CE]
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_99ED3D648751]
Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
Ebrahimi-Nik H., Michaux J., Corwin W.L., Keller G.L., Shcheglova T., Pak H., Coukos G., Baker B.M., Mandoiu I.I., Bassani-Sternberg M. et al., 2019/06/20. JCI insight, 5. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_77410C339277]
 
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants.
Messaoudene M., Mourikis T.P., Michels J., Fu Y., Bonvalet M., Lacroix-Trikki M., Routy B., Fluckiger A., Rusakiewicz S., Roberti M.P. et al., 2019/06/01. Annals of oncology, 30 (6) pp. 934-944. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BF300CC80761]
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A5A6B3310C5]
 
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.
Mookerjee A., Graciotti M., Kandalaft L.E., 2019..
[DOI][Pmid][serval:BIB_35871AE4DC06]
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
Yakkala C., Chiang C.L., Kandalaft L., Denys A., Duran R., 2019. Frontiers in immunology, 10 p. 2283. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_60A056CC233D]
Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
Van Nuffel AMT, Boudousquié C., Tuyaerts S., 2019. Frontiers in immunology, 10 p. 2032. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E27769E626CB]
Editorial: Novel Strategies for Anti-Tumor Vaccines.
Accolla R.S., Buonaguro L., Melief C., Rammensee H.G., Bassani-Sternberg M., 2019. Frontiers in immunology, 10 p. 3117. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_174539D18793]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
Mastelic-Gavillet B., Balint K., Boudousquie C., Gannon P.O., Kandalaft L.E., 2019. Frontiers in immunology, 10 p. 766. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D40F225C7046]
2018
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Martin Lluesma S., Graciotti M., Chiang C.L., Kandalaft L.E., 2018/11/23. Vaccines, 6 (4). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3145728F3A3C]
 
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Coscia F., Lengyel E., Duraiswamy J., Ashcroft B., Bassani-Sternberg M., Wierer M., Johnson A., Wroblewski K., Montag A., Yamada S.D. et al., 2018/09/20. Cell, 175 (1) pp. 159-170.e16. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_276E8E11EA5C]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE6933D4F057]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
 
Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K., Soltermann A., Attar F.M., Casanova R., Uckeley Z.M., Thut H., Wandres M., Isajevs S., Cheng P., Curioni-Fontecedro A. et al., 2018/03/01. Cancer research, 78 (5) pp. 1308-1320. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DEA67BEAD51D]
 
Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y., Hu J., Wang Y., Peng X., Min J., Wang J., Matthaiou E., Cheng Y., Sun K., Tong X. et al., 2018/02. European journal of cancer, 90 pp. 111-121. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E091004637B]
Cellular Composition and Contribution of Tertiary Lymphoid Structures to Tumor Immune Infiltration and Modulation by Radiation Therapy.
Boivin G., Kalambaden P., Faget J., Rusakiewicz S., Montay-Gruel P., Meylan E., Bourhis J., Lesec G., Vozenin M.C., 2018. Frontiers in oncology, 8 p. 256. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_64E7EAD7D9CF]
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
Tsoutsou P.G., Zaman K., Martin Lluesma S., Cagnon L., Kandalaft L., Vozenin M.C., 2018. Frontiers in oncology, 8 p. 609. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F237867AE06]
2017
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
Graciotti M., Berti C., Klok H.A., Kandalaft L., 2017/06/19. Journal of translational medicine, 15 (1) p. 142. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_860F405AA782]
 
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R., Dafni U., Felip E., Curioni-Fontecedro A., Gautschi O., Peters S., Massutí B., Palmero R., Aix S.P., Carcereny E. et al., 2017/05. The Lancet. Respiratory medicine, 5 (5) pp. 435-444. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6307005064D]
Heterogeneity assessment of functional T cell avidity.
Ioannidou K., Baumgaertner P., Gannon P.O., Speiser M.F., Allard M., Hebeisen M., Rufer N., Speiser D.E., 2017/03/13. Scientific reports, 7 p. 44320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_39C885ED43A7]
Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.
Bassani-Sternberg M., Chong C., Guillaume P., Solleder M., Pak H., Gannon P.O., Kandalaft L.E., Coukos G., Gfeller D., 2017. PLoS Computational Biology, 13 (8) pp. e1005725. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F969601F848]
 
Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin.
Vigano S., Trabanelli S., Indulsi F., Salomé B., Harari A., Romero P., Helbling A., Jandus C., Jandus P., 2017. Journal of investigational allergology & clinical immunology, 27 (6) pp. 394-396. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AFE710182D6B]
2016
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Martin Lluesma S., Wolfer A., Harari A., Kandalaft L.E., 2016/05/03. Biomedicines, 4 (2) pp. NA. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3E1510893037]
 
Current tools for predicting cancer-specific T cell immunity.
Gfeller D., Bassani-Sternberg M., Schmidt J., Luescher I.F., 2016. Oncoimmunology, 5 (7) pp. e1177691. Peer-reviewed.
[DOI][Pmid][serval:BIB_D584F684242A]
Multiplexed tissue biomarker imaging.
Stack E.C., Foukas P.G., Lee P.P., 2016. Journal For Immunotherapy of Cancer, 4 p. 9. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_29FE609A2239]
 
Personalized approaches to active immunotherapy in cancer
Ophir Eran, Bobisse Sara, Coukos George, Harari Alexandre, Kandalaft Lana E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 72-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01C8158A4FDC]
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A6A68301DF3E]
2015
 
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Copie-Bergman C., Cuillière-Dartigues P., Baia M., Briere J., Delarue R., Canioni D., Salles G., Parrens M., Belhadj K., Fabiani B. et al., 2015. Blood, 126 (22) pp. 2466-2474. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_518A1846CD43]
2014
 
Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E., Tanyi J., Balint K., Kandalaft L.E., 2014/09. Current opinion in oncology, 26 (5) pp. 492-500. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D9F55B9E77A]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University